Bfsg, LLC Bristol Myers Squibb CO Transaction History

Bfsg, LLC

$774 Million
Q2 2024

A detailed history of Bfsg, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bfsg, LLC holds 720 shares of BMY stock, worth $37,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares

720

Previous 1,120 35.71%

Holding current value

$37,260

Previous $60,000 51.67%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$40.25 - $52.99 $16,100 - $21,196	-400 Reduced 35.71%	720 $29,000
Q1 2024 Apr 23, 2024	BUY	$47.98 - $54.4 $10,555 - $11,968	220 Added 24.44%	1,120 $60,000
Q4 2023 Feb 01, 2024	BUY	$48.48 - $57.85 $43,632 - $52,065	900 New	900 $46,000
Q2 2021 Jul 29, 2021	SELL	$61.91 - $67.42 $5.62 Million - $6.12 Million	-90,840 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$59.34 - $66.74 $232,968 - $262,021	-3,926 Reduced 4.14%	90,840 $5.74 Million
Q4 2020 Jan 26, 2021	BUY	$57.74 - $65.43 $4.98 Million - $5.64 Million	86,275 Added 1016.08%	94,766 $5.88 Million
Q3 2020 Nov 04, 2020	SELL	$57.43 - $63.64 $2.03 Million - $2.25 Million	-35,388 Reduced 80.65%	8,491 $512,000
Q2 2020 Jul 22, 2020	BUY	$54.82 - $64.09 $1.99 Million - $2.33 Million	36,280 Added 477.43%	43,879 $2.58 Million
Q1 2020 Apr 27, 2020	SELL	$46.4 - $67.43 $322,433 - $468,571	-6,949 Reduced 47.77%	7,599 $424,000
Q4 2019 Jan 29, 2020	BUY	$49.21 - $64.19 $450,320 - $587,402	9,151 Added 169.56%	14,548 $934,000
Q3 2019 Oct 25, 2019	BUY	$42.77 - $50.71 $230,829 - $273,681	5,397 New	5,397 $267,000

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bfsg, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bfsg, LLC with notifications on news.

Account